Phone Line Dropped Calls

SIU Medicine's primary phone line, 217-545-8000, is experiencing intermittent dropped calls. We apologize for this inconvenience and are working to correct this issue as soon as possible.


Study of Green Tea Extract May Yield Key to Hearing Protection for Cancer Patients

Published Date:

SPRINGFIELD, ILLINOIS: If you could take a drug that would help cure your cancer, but it would make you go deaf, would you still take the drug?

Cisplatin is a widely used anticancer drug that unfortunately carries some major side effects, including hearing loss and damage to the nerves and kidneys. Its high toxicity often requires dose reductions or the use of less effective alternate drugs.

Cisplatin-induced hearing loss can range from 50-75 percent in adults. When the drug is used to treat neuroblastomas in pediatric cancer patients, extreme care must be taken because hearing loss can hamper speech, cognition and social development of the child.

Vickram Ramkumar, PhD, professor of pharmacology at SIU School of Medicine, has received a new $2.3 million grant from the National Institutes of Health (NIH) to explore the properties of a green tea extract, epigallocatechin gallate (EGCG), which offers protection against cisplatin-induced hearing loss. It builds upon his lab’s ototoxicity research with Debashree Mukherjea, PhD, assistant research professor, and Leonard Rybak, MD, professor emeritus, both in the Division of Otolaryngology, Department of Surgery.

“Chemotherapy can be daunting, so anything you can do to end a side effect and ease the patient’s recovery is a win,” said Dr. Ramkumar. “We are encouraged that our studies could lead to the design of a safer treatment for cancer care.”

The research team had earlier identified a protein called signal transducer and activator of transcription 1 (STAT1) that is involved in the activation of inflammation and cell death pathway in the ear induced by cisplatin. The new studies will test how STAT1 is affected by different doses of the green tea extract EGCG, and examine if it has different benefits by gender and by timing of the doses. The group will also examine whether EGCG interferes with the anticancer benefits of cisplatin, as these drugs will be administered together to treat cancer (cisplatin) or reduce hearing loss (EGCG).

More from SIU News

Farm succession series header

SIU Medicine offers virtual series on farm succession planning

Join us for an upcoming live virtual series, "Planning for the Farm's Future and Yours." The FFRI programs are designed to assist farmers and farm families in developing a succession plan for future generations.
Raj @ 3-Minute Thesis

Pharmacology grad student wins SIU 3-Minute Thesis competition

A trio of School of Medicine graduate students put their presentation skills to the test at the Three-Minute Thesis (3MT) competition on the Carbondale campus February 2. They summarized their research in 3 minutes or less using a single PowerPoint slide.
Valentine bear care at Doll Clinic

Doll Clinic offers children gentle guide to a doctor’s visit

The Doll Clinic is a community service that SIU Medicine’s Physician Assistant Program coordinates annually for SIU Head Start. The host sites alternate every year between Carbondale, Marion and Murphysboro. This year, morning and afternoon sessions were held at SIU Marion Head Start on February 8.